2 citations
,
May 2023 in “The Journal of Immunology” This animal study observed that treatment with the S1PR modulator NXC736 significantly reduced lesion area and CD8+ T cell infiltration in mice with alopecia areata, suggesting its potential as a promising therapy for the condition.
50 citations
,
November 2021 in “Viruses” This study observed that in vitro exposure to dihydrotestosterone worsened COVID-19 spike protein-induced endothelial injury, while spironolactone showed potential in reducing this effect, suggesting a rationale for further evaluation in treating COVID-19.
49 citations
,
November 2021 in “Annual review of pathology” This review discusses the regulatory roles of lysophospholipids like LPA and S1P in diseases such as fibrosis, neuropathic pain, and cancer, but reports no new clinical results.
November 2025 in “Frontiers in Immunology” This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.
1 citations
,
January 2018 This study found that sphingosine 1-phosphate and its receptor S1PR3 are essential in regulating the acute mechanical pain response, highlighting their role in mechanonociception without affecting responses to innocuous touch or thermal stimuli.